Robert Ross

50 year

Health Technology

Consumer Services

Profile

Robert W.
Ross is an Independent Director at Xilio Therapeutics, Inc. since 2022.
He is also a Director at Obsidian Therapeutics, Inc. since 2020.
Prior to his current positions, he served as the President of Surface Oncology, Inc. from 2016 to present.
Before that, he was the Senior Vice President-Clinical Development at bluebird bio, Inc. from 2015 to 2016.
Dr. Ross completed his undergraduate studies at Stanford University and pursued graduate degrees at Harvard Medical School and Columbia University College of Physicians & Surgeons.

Robert Ross active positions

Companies	Position	Start
SURFACE ONCOLOGY, INC.	President	-
XILIO THERAPEUTICS, INC.	Director/Board Member	2022-06-15
Obsidian Therapeutics, Inc. Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA.	Director/Board Member	2020-09-02

All active positions of Robert Ross

Former positions of Robert Ross

Companies	Position	End
BLUEBIRD BIO, INC.	Corporate Officer/Principal	2016-09-30

See the detail of Robert Ross's experience

Training of Robert Ross

Stanford University	Undergraduate Degree
Harvard Medical School	Graduate Degree
Columbia University College of Physicians & Surgeons	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Robert Ross's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
BLUEBIRD BIO, INC.	Health Technology
XILIO THERAPEUTICS, INC.	Health Technology

Private companies	2
Surface Oncology, Inc. Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.	Health Technology
Obsidian Therapeutics, Inc. Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA.	Health Technology